Pseudolaric Acid B Inhibits Proliferation, Invasion, and Angiogenesis in Esophageal Squamous Cell Carcinoma Through Regulating CD147

References

• ChenW, ZhengR, BaadePD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• RustgiA, El-SeragHB. Esophageal carcinoma. N Engl J Med. 2015;372(15):1472–1473.
   PubMedGoogle Scholar
• MurtaCB, AntunesAA, Dall’OglioMF, MosconiA, LeiteKR, SrougiM. Analysis of the clinicopathological characteristics of patients with upper urinary tract transitional cell carcinoma. Clinics. 2008;63(2):223–228.18438577
   PubMed Web of Science ®Google Scholar
• DuttonSJ, FerryDR, BlazebyJM, et al. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a Phase 3, multicentre, double-blind, placebo-controlled randomised trial. Lancet Oncol. 2014;15(8):894–904.24950987
   PubMed Web of Science ®Google Scholar
• AndoN, OzawaS, KitagawaY, ShinozawaY, KitajimaM. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg. 2000;232(2):225–232.10903602
   PubMed Web of Science ®Google Scholar
• LiT, WangW, LiYX, et al. Pseudolaric acid B attenuates atherosclerosis progression and inflammation by suppressing PPARgamma-mediated NF-kappaB activation. Int Immunopharmacol. 2018;59:76–85.29631101
   PubMed Web of Science ®Google Scholar
• WangZ, DingY, WangX, et al. Pseudolaric acid B triggers ferroptosis in glioma cells via activation of Nox4 and inhibition of xCT. Cancer Lett. 2018;428:21–33.29702192
   PubMed Web of Science ®Google Scholar
• LiS, GuoL. [Pseudolaric acid B induces G2/M arrest and inhibits invasion and migration in HepG2 hepatoma cells]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2018;34(1):59–64. Chinese.29595459
   PubMedGoogle Scholar
• ChoiSJ, AhnCH, YangIH, et al. Pseudolaric Acid B Induces Growth Inhibition and Caspase-Dependent Apoptosis on Head and Neck Cancer Cell lines through Death Receptor 5. Molecules. 2019;24:20.
   Web of Science ®Google Scholar
• GuanD, LiC, LvX, YangY. Pseudolaric acid B inhibits PAX2 expression through Wnt signaling and induces BAX expression, therefore promoting apoptosis in HeLa cervical cancer cells. J Gynecol Oncol. 2019;30(5):e77. doi:10.3802/jgo.2019.30.e7731328459
   PubMed Web of Science ®Google Scholar
• Evidence-BasedC, AlternativeM. Expression of Concern on “Pseudolaric Acid B Induces Caspase-Dependent and Caspase-Independent Apoptosis in U87 Glioblastoma Cells”. Evid Based Complement Alternat Med. 2019;2019:4959838.31531113
   PubMed Web of Science ®Google Scholar
• ZhangH, LiJ-C, LuoH, ZhaoL, ZhangZ-D, ShenX-F. Pseudolaric acid B exhibits anti-cancer activity on human hepatocellular carcinoma through inhibition of multiple carcinogenic signaling pathways. Phytomedicine. 2019;59:152759. doi:10.1016/j.phymed.2018.11.01931004883
   PubMed Web of Science ®Google Scholar
• PanthoAF, PriceM, AshrafAZ, et al. Synthetic Receptors Induce Anti Angiogenic and Stress Signaling on Human First Trimester Cytotrophoblast Cells. Int J Environ Res Public Health. 2017;14(5):5. doi:10.3390/ijerph14050517
   Web of Science ®Google Scholar
• TongY-G, ZhangX-W, GengM-Y, et al. Pseudolarix acid B, a new tubulin-binding agent, inhibits angiogenesis by interacting with a novel binding site on tubulin. Mol Pharmacol. 2006;69(4):1226–1233. doi:10.1124/mol.105.02053716424078
   PubMed Web of Science ®Google Scholar
• LiM-H, et al. Pseudolaric Acid B Inhibits Angiogenesis and Reduces Hypoxia-Inducible Factor 1 by Promoting Proteasome-Mediated Degradation. Clin Cancer Res. 2004;10(24):8266–8274. doi:10.1158/1078-0432.CCR-04-095115623602
   PubMed Web of Science ®Google Scholar
• ZhouY, DiZ, LiX, et al. Chemical proteomics reveal CD147 as a functional target of pseudolaric acid B in human cancer cells. Chem Commun (Camb). 2017;53(62):8671–8674. doi:10.1039/C7CC04345G28721406
   PubMed Web of Science ®Google Scholar
• EgawaN, KoshikawaN, TomariT, NabeshimaK, IsobeT, SeikiM. Membrane type 1 matrix metalloproteinase (MT1-MMP/MMP-14) cleaves and releases a 22-kDa extracellular matrix metalloproteinase inducer (EMMPRIN) fragment from tumor cells. J Biol Chem. 2006;281(49):37576–37585. doi:10.1074/jbc.M60699320017050542
   PubMed Web of Science ®Google Scholar
• XuT, ZhouM, PengL, et al. Upregulation of CD147 promotes cell invasion, epithelial-to-mesenchymal transition and activates MAPK/ERK signaling pathway in colorectal cancer. Int J Clin Exp Pathol. 2014;7(11):7432–7441.25550778
   PubMed Web of Science ®Google Scholar
• WuJ, RuNY, ZhangY, et al. HAb18G/CD147 promotes epithelial-mesenchymal transition through TGF-beta signaling and is transcriptionally regulated by Slug. Oncogene. 2011;30(43):4410–4427.21532623
   PubMed Web of Science ®Google Scholar
• YangS, QiF, TangC, et al. CD147 promotes the proliferation, invasiveness, migration and angiogenesis of human lung carcinoma cells. Oncol Lett. 2017;13(2):898–904.28356976
   PubMed Web of Science ®Google Scholar
• IshibashiY, MatsumotoT, NiwaM, et al. CD147 and matrix metalloproteinase-2 protein expression as significant prognostic factors in esophageal squamous cell carcinoma. Cancer. 2004;101(9):1994–2000.15372476
   PubMed Web of Science ®Google Scholar
• ChengMF, TzaoC, TsaiWC, et al. Expression of EMMPRIN and matriptase in esophageal squamous cell carcinoma: correlation with clinicopathological parameters. Dis Esophagus. 2006;19(6):482–486.17069593
   PubMed Web of Science ®Google Scholar
• ZhuS, LiY, MiL, et al. Clinical impact of HAb18G/CD147 expression in esophageal squamous cell carcinoma. Dig Dis Sci. 2011;56(12):3569–3576.21789540
   PubMed Web of Science ®Google Scholar
• YaoGD, YangJ, LiXX, et al. Blocking the utilization of glucose induces the switch from senescence to apoptosis in pseudolaric acid B-treated human lung cancer cells in vitro. Acta Pharmacol Sin. 2017;38(10):1401–1411.28649131
   PubMed Web of Science ®Google Scholar
• SunQ, LiY. The inhibitory effect of pseudolaric acid B on gastric cancer and multidrug resistance via Cox-2/PKC-alpha/P-gp pathway. PLoS One. 2014;9(9):e107830.25250794
   PubMed Web of Science ®Google Scholar
• ZhaoD, LinF, WuX, et al. Pseudolaric acid B induces apoptosis via proteasome-mediated Bcl-2 degradation in hormone-refractory prostate cancer DU145 cells. Toxicol in Vitro. 2012;26(4):595–602.22388098
   PubMed Web of Science ®Google Scholar
• LiM, HongL. Pseudolaric acid B exerts antitumor activity via suppression of the Akt signaling pathway in HeLa cervical cancer cells. Mol Med Rep. 2015;12(2):2021–2026.25891953
   PubMed Web of Science ®Google Scholar
• KhanM, ZhengB, YiF, et al. Pseudolaric Acid B induces caspase-dependent and caspase-independent apoptosis in u87 glioblastoma cells. Evid Based Complement Alternat Med. 2012;2012:957568.22778780
   PubMed Web of Science ®Google Scholar
• LiX, ZhaoX, SongW, et al. Pseudolaric Acid B Inhibits Proliferation, Invasion and Epithelial-to-Mesenchymal Transition in Human Pancreatic Cancer Cell. Yonsei Med J. 2018;59(1):20–27.29214772
   PubMed Web of Science ®Google Scholar
• YuJ, RenP, ZhongT, et al. Pseudolaric acid B inhibits proliferation in SW579 human thyroid squamous cell carcinoma. Mol Med Rep. 2015;12(5):7195–7202.26460192
   PubMed Web of Science ®Google Scholar
• WenC, ChenJ, ZhangD, et al. Pseudolaric acid B induces mitotic arrest and apoptosis in both 5-fluorouracil-sensitive and -resistant colorectal cancer cells. Cancer Lett. 2016;383(2):295–308.27713084
   PubMed Web of Science ®Google Scholar
• TianL, ZhangY, ChenY, CaiM, DongH, XiongL. EMMPRIN is an independent negative prognostic factor for patients with astrocytic glioma. PLoS One. 2013;8(3):e58069.23516431
   PubMed Web of Science ®Google Scholar
• LiuF, CuiL, ZhangY, et al. Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma. Breast Cancer Res Treat. 2010;124(3):677–688.20213083
   PubMed Web of Science ®Google Scholar
• JuXZ, YangJM, ZhouXY, LiZT, WuXH. EMMPRIN expression as a prognostic factor in radiotherapy of cervical cancer. Clin Cancer Res. 2008;14(2):494–501.18223224
   PubMed Web of Science ®Google Scholar
• NakamuraK, KodamaJ, HongoA, HiramatsuY. Role of emmprin in endometrial cancer. BMC Cancer. 2012;12:191.22640183
   PubMed Web of Science ®Google Scholar
• ZhaoY, ChenS, GouWF, et al. The role of EMMPRIN expression in ovarian epithelial carcinomas. Cell Cycle. 2013;12(17):2899–2913.23966157
   PubMed Web of Science ®Google Scholar
• BisacchiD, BenelliR, VanzettoC, FerrariN, TosettiF, AlbiniA. Anti-angiogenesis and angioprevention: mechanisms, problems and perspectives. Cancer Detect Prev. 2003;27(3):229–238.12787731
   PubMedGoogle Scholar
• LianL, LiXL, XuMD, et al. VEGFR2 promotes tumorigenesis and metastasis in a pro-angiogenic-independent way in gastric cancer. BMC Cancer. 2019;19(1):183.30819137
   PubMed Web of Science ®Google Scholar
• SorokinM, PoddubskayaE, BaranovaM, et al. RNA sequencing profiles and diagnostic signatures linked with response to ramucirumab in gastric cancer. Cold Spring Harb Mol Case Stud. 2020;6:2.
   Web of Science ®Google Scholar